Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Benitec Reports $45.5 Million Full-Year Loss as BB-301 Trial Advances

None

Benitec Biopharma (BNTC) reported a net loss attributable to shareholders of $45.5 million, or $0.98 per basic and diluted share, for the fiscal year ended June 30, 2026. The company reported $180.0 million in cash and cash equivalents at year-end.

The company said all six low-dose BB-301 Cohort 1 patients completed 12-month follow-up, while the three-patient high-dose Cohort 2 was fully enrolled and treated. Benitec expects to initiate a BB-301 pivotal trial in mid-2027.

  • Total operating expenses were $51.2 million, compared with $41.8 million in fiscal 2025.
  • Research and development expenses were $23.4 million; general and administrative expenses were $27.8 million.
  • Benitec held an FDA Type C meeting in the third quarter of 2026 regarding BB-301 pivotal-study design, with meeting minutes anticipated in October.
  • Interim BB-301 Phase 1b/2a results are scheduled for presentation at the ESGCT Annual Congress in Hamburg, Germany, on October 27-30, 2026.
EARLY ACCESS
Receive BNTC Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$BNTC Hedge Fund Activity

We have seen 50 institutional investors add shares of $BNTC stock to their portfolio, and 36 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • SIREN, L.L.C. removed 775,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,253,750
  • SIMPLIFY ASSET MANAGEMENT INC. added 443,315 shares (+78.8%) to their portfolio in Q2 2026, for an estimated $5,931,554
  • NANTAHALA CAPITAL MANAGEMENT, LLC added 400,000 shares (+38.5%) to their portfolio in Q1 2026, for an estimated $4,260,000
  • MILLENNIUM MANAGEMENT LLC added 269,235 shares (+41.3%) to their portfolio in Q2 2026, for an estimated $3,602,364
  • BLACKROCK, INC. added 221,397 shares (+18.7%) to their portfolio in Q2 2026, for an estimated $2,962,291
  • CITADEL ADVISORS LLC added 154,142 shares (+876.8%) to their portfolio in Q1 2026, for an estimated $1,641,612
  • LONGAEVA PARTNERS L.P. removed 110,126 shares (-88.1%) from their portfolio in Q2 2026, for an estimated $1,473,485

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles